Monocyte Chemoattractant Protein 1 Promotes VEGF-A Expression in OSCC by Activating ILK and MEK1/2 Signaling and Downregulating miR-29c

Oral squamous cell carcinoma (OSCC) is an aggressive tumor that has a poor prognosis, with high levels of local invasion and lymph node metastasis. Vascular endothelial growth factor A (VEGF-A) plays essential roles in OSCC tumor angiogenesis and metastasis. Monocyte chemoattractant protein-1 (MCP-1...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 10; p. 592415
Main Authors Lien, Ming-Yu, Chang, An-Chen, Tsai, Hsiao-Chi, Tsai, Ming-Hsui, Hua, Chun-Hung, Cheng, Shih-Ping, Wang, Shih-Wei, Tang, Chih-Hsin
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 27.11.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Oral squamous cell carcinoma (OSCC) is an aggressive tumor that has a poor prognosis, with high levels of local invasion and lymph node metastasis. Vascular endothelial growth factor A (VEGF-A) plays essential roles in OSCC tumor angiogenesis and metastasis. Monocyte chemoattractant protein-1 (MCP-1, CCL2) is implicated in various inflammatory conditions and pathological processes, including oral cancer. The existing evidence has failed to confirm any correlation between MCP-1 or VEGF-A expression and OSCC angiogenesis. In this study, high expression levels of MCP-1 and VEGF-A were positively correlated with disease stage in patients with OSCC. In oral cancer cells, MCP-1 increased VEGF-A expression and subsequently promoted angiogenesis; miR-29c mimic reversed MCP-1 activity. We also found that MCP-1 modulated VEGF-A expression and angiogenesis through CCR2/ILK/MEK1/2 signaling. Ex vivo results of the chick embryo chorioallantoic membrane (CAM) assay revealed the angiogenic qualities of MCP-1, with increased numbers of visible blood vessel branches. Our data suggest that MCP-1 is a new molecular therapeutic target for the inhibition of angiogenesis and metastasis in OSCC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Ming Yann Lim, Tan Tock Seng Hospital, Singapore
This article was submitted to Head and Neck Cancer, a section of the journal Frontiers in Oncology
These authors have contributed equally to this work
Reviewed by: Cheng-Chia Yu, Chung Shan Medical University, Taiwan; Hong-Quan Duong, Hanoi University of Public Health, Vietnam
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2020.592415